“…The following primary antibodies were used for IB and IF: rabbit anti‐cingulin C532 (1:5000 IB, 1:10000 IF), mouse anti‐cingulin 22BD5A1 (1:30 IB), rabbit anti‐paracingulin n.821 (1:10000 IB, 1:100 IF), mouse anti‐paracingulin (E‐6) (1:1000 IB, Santa Cruz, sc‐377525), mouse anti‐ZO‐1 (1:1000 IB, 1:5000 IF, Invitrogen, 33–9100), rabbit anti‐ZO‐2 (H‐110) (1:1000 IB, Santa Cruz, sc‐11448), rabbit anti‐ZO‐3 (1:2000 IB, Invitrogen, 36–4100), mouse anti‐occludin (1:1000 IB, 1:100 IF, Invitrogen, 33–1500), rabbit anti‐occludin (1:1000 IB, 1:100 IF, Invitrogen, 71–1500), rabbit anti‐PLEKHA7 R30388 (1:2000 IB, 1:500 IF), guinea pig anti‐PLEKHA7 GP2737 (1:500 IF), rabbit anti‐afadin (1:8000 IB, 1:100 IF, Sigma, A0224), rabbit anti‐PDZD11 (1:1000 IB, 29958), mouse anti‐p120‐catenin (1:2000 IB, 1:250 IF, 15D2, a kind gift of Prof. A. Reynolds, Vanderbilt University Nashville, TN,) rabbit anti‐α‐catenin (1:8000 IB, 1:500 IF, Sigma, C2081), mouse anti‐E‐cadherin (1:8000 IB, 1:2000 IF, BD610181, which crossreacts with P‐cadherin (http://www.bdbiosciences.com/ds/pm/tds/610181.pdf)), goat anti‐VE‐cadherin (C‐19) (1:1000 IB, 1:50 IF, Santa Cruz, sc‐6458), rabbit anti‐pan‐cadherin (1:1000 IB, 1:100 IF, Sigma, C3678), and mouse anti‐β‐tubulin (1:4000 IB, Invitrogen, 32–2600). The specificity of primary antibodies against CGN, CGNL1, PLEKHA7, and PDZD11 was validated in our laboratory using depleted or knockout (KO) cells.…”